Sirtex completes acquisition of FDA-cleared Hourglass, GRAND PHARMA (00512) further upgrades its precision intervention ecosystem synergy capabilities
GRAND PHARMA (00512)'s associate company Sirtex has recently acquired the FDA 510(k)-cleared Hourglass vascular embolization plug and related product assets, further expanding the company's precision intervention diagnosis and treatment product matrix. The product is expected to create procedural synergy with Yigantai "preoperative collateral embolization + intraoperative intratumoral radiation" and drive commercial expansion into peripheral vascular, emergency hemostasis and other fields.
Sirtex completes acquisition of FDA-cleared Hourglass, GRAND PHARMA (00512) further upgrades its precision intervention ecosystem synergy capabilities
Hong Kong-listed innovative biopharmaceutical company GRAND PHARMA (00512) has welcomed a new member to its global innovative product matrix its associate company Sirtex Medical Pty Ltd recently added the FDA 510(k)-cleared Hourglass embolization plug and related product assets to its portfolio. For GRAND PHARMA, this marks another move in the continuous global expansion of its interventional diagnosis and treatment product pipeline.
Public information shows that the Hourglass features a self-expanding nitinol braided mesh frame, with the proximal half covered by an ultra-thin PTFE membrane and the distal end anchored by a bare mesh frame. Blood flow impact pressure helps the frame conform to the vessel wall, and the device supports recapture and repositioning before full deployment. The device is compatible with 68mm peripheral vessels; its approved indications do not include aneurysm occlusion, and contraindications cover vessels in the extremities with active flow and the pulmonary artery. This design provides immediate vessel occlusion while helping to improve anchoring stability, reduce the risk of post-operative device migration, and give operators tolerance for handling complex tortuous vascular anatomy.
Taking a longer view, the addition of Hourglass is merely the latest step in GRAND PHARMA's continuous expansion in the technology fields of radiopharmaceutical anti-tumor diagnosis and treatment and cardio-cerebrovascular precision interventional diagnosis and treatment. In April this year, the company's flagship radiopharmaceutical product YiganTai (yttrium[90Y] microsphere injection) successfully reached its clinical endpoint in the DOORwaY90 clinical study conducted in the United States. The FDA had previously approved its new indication for unresectable HCC based on the breakthrough interim data from this study, making it the world's first and only selective internal radiation therapy product approved by the FDA to cover both unresectable HCC and colorectal cancer liver metastases. LAVA liquid embolic agent achieved commercialization in the United States in October 2023 and continues to ramp up rapidly. From radiopharmaceuticals to embolization devices, a series of densely delivered milestones is outlining GRAND PHARMA's strategic depth in high-barrier tracks.
New embolization product fills interventional pipeline gap, precision diagnosis and treatment platform synergistically expands
The integration of Hourglass is expected to form substantive procedural synergy with YiganTai. Before performing yttrium-90 radioactive microsphere therapy, physicians often need to first use embolization devices to occlude collateral vessels such as the gastroduodenal artery to prevent radioactive microspheres from ectopically flowing into the gastrointestinal tract and causing adverse reactions. With the addition of Hourglass, GRAND PHARMA is expected to further cover a one-stop solution of "pre-operative collateral occlusion + intra-operative intratumoral radiation," linking the two products from independent devices into consecutive steps within the same surgical procedure. This synergy is not a simple but a product fill positioned around the actual pathway of interventional procedures.
Looking further ahead, the indication boundaries of Hourglass also imply new market space. Beyond tumor intervention, the product can be used in routine interventional scenarios such as peripheral vascular malformations and trauma bleeding control, which is expected to drive the company's commercialization team to extend from tumor intervention departments to broader fields including peripheral vascular disease and emergency hemostasis. From access management to vascular embolization, GRAND PHARMA's precision interventional diagnosis and treatment product matrix is continuously extending, and its platform-based layout is becoming increasingly clear, providing more complete product support for the company's subsequent global commercialization of products.
Global layout advances in depth, industrial chain synergy continues to improve
This acquisition reflects precisely GRAND PHARMA's continuously deepening overall global layout from the overseas clinical breakthrough of yttrium-90 microspheres and the commercialization of LAVA in the United States to the inclusion of this globally mature embolization asset. GRAND PHARMA is continuously integrating global innovative resources, connecting mature overseas products to its own platform, and steadily enhancing its ability to allocate innovative assets globally. The company is persistently practicing its "Go Global" global innovation development strategy.
In addition to its rich product pipeline layout, in global R&D, GRAND PHARMA has established extensive cooperation with leading global pharmaceutical companies, universities and research institutions, providing front-end touchpoints for the identification, introduction and transformation of innovative assets. Meanwhile, the company has established multiple R&D technology platforms and R&D centers to support the continuous incubation and implementation of more innovative products. In the radiopharmaceutical anti-tumor diagnosis and treatment segment, the company's Boston R&D center in the United States and Chengdu radiopharmaceutical R&D center in China have respectively built a tumor intervention technology platform and an RDC technology platform.
In the first half of 2026, GRAND PHARMA had 34 innovative projects in research reserve, with R&D investment of approximately HK$760 million, and recorded 18 major milestone progresses. On the registration front, the company's global clinical and "China-U.S. dual filing" registration system is becoming increasingly mature. Multiple products have obtained clinical permits from international drug regulatory authorities, core product clinical results have been published in top international journals, and products have successively been included in authoritative diagnosis and treatment guidelines at home and abroad. The capability accumulation from early discovery to international registration constitutes the infrastructure for the company to undertake global innovative assets.
At the industrial chain level, the company has built a full-chain capability covering "early discovery preclinical research registration filing clinical development commercialization." From the acquisition of innovative assets and the advancement of clinical registration to commercialization, GRAND PHARMA is connecting the complete closed loop of innovation value with full industrial chain capabilities. The inclusion of the Hourglass asset is a concrete example of this closed loop: a mature device that has completed overseas clinical validation and crossed regulatory thresholds enters the company's product matrix through global resource integration, and then advances ramp-up relying on existing channels and clinical networks, with capabilities at each stage closely interlocked and linked in an orderly manner.
From early positioning in high-barrier tracks to building a global R&D and registration network, and then to continuously adding mature assets through integration of innovative resources, GRAND PHARMA's foresight and strategic resolve in industrial chain layout run throughout. Looking ahead, GRAND PHARMA stated that the company will continue to deepen its global innovation strategy, improve its full-chain R&D and commercialization system, accelerate the implementation of innovative products, and provide more advanced and diverse treatment options for patients worldwide.
Related Articles

New stock news | Hearing passed! Kunlun New Materials' half-year results exceed the whole of last year, and the world's third-largest independent electrolyte manufacturer is about to list on the Hong Kong stock market.

BAMA TEA (06980) responds to suspension of military procurement qualification: it is a qualification adjustment in a specific field and has no impact on the group's public-facing sales, operations, and core business.

YUM CHINA (09987) repurchased approximately 111,500 shares for approximately US$5.5999 million on November 20.
New stock news | Hearing passed! Kunlun New Materials' half-year results exceed the whole of last year, and the world's third-largest independent electrolyte manufacturer is about to list on the Hong Kong stock market.

BAMA TEA (06980) responds to suspension of military procurement qualification: it is a qualification adjustment in a specific field and has no impact on the group's public-facing sales, operations, and core business.

YUM CHINA (09987) repurchased approximately 111,500 shares for approximately US$5.5999 million on November 20.






